FDA Approves ‘First-in-Class’ NDSRI for ADHD in Adults and Children
2 sources·Updated July 30, 2026
Covered by 2 sources
- Medical Xpress·2h agoFDA approves Simtriyo for treating ADHD in children and adults
The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
Read at Medical Xpress → - Healthline News·15h agoFDA Approves ‘First-in-Class’ NDSRI for ADHD in Adults and Children
SIMTRIYO is a newly approved central nervous system medication to help treat ADHD in children and adults. Tom Werner/DigitalVision/Getty Images Federal regulators have approved a new medication to help manage attention deficit hyperactivity disorder (ADHD). SIMTRIYO is a daily…
Read at Healthline News →
